Conference Agenda

Friday, April 24th, 2026: Pre Conference

Cellular Processing Laboratory Workshop

8:30 AM - 8:45 AM

Opening

Celattin Ustun, MD & Mahzad Akbapour, PhD

8:45 AM - 9:15 AM

Global Cell Therapy Lab Leadership or Hospital Based Point of Care Cell Therapy Manufacturing

Jacques Galipeau, MD

9:15 AM - 9:45 AM

Operationalizing Point-of-Care Stem Cell Processing & cGMP Cell Therapy Manufacturing in Academic Hospitals: Lessons from Rush MD Anderson Cancer Center

Mahzad Akbapour, PhD            
9:45 AM - 10:15 AM

Advancing Cell Therapies: Stability of Cryopreserved HSPCs and Off-the-Shelf Bridge Grafts to Treat Cancer Therapy Associated Cytopenia

Nadim Mahmud MD PhD

10:15 AM - 10:45 AM

Mesenchymal Stem Cell Therapy for Ocular Injuries

Ali Djalilian MD, PhD

10:45 AM - 11:00 AM

Coffee Break

11:00 AM - 11:30 AM

Miltenyi CAR T Cell Research and Development

CAR (chimeric antigen receptor) strategies to lower cost and improve efficacy

Rimas Orentas PhD

11:30 AM - 12:30 PM

Miltenyi Clinical Hands on Lab (2 rounding sessions- 30 min each round)

12:30 PM - 1:00 PM

Lunch Break

1:00 PM - 1:30 PM

Jos Melennhorst Lab

Jan Joseph Melenhorst PhD

1:30 PM - 2:00 PM

Immuno-monitoring and Analytical Assay Development Form Point of Care cGMP Cell Manufacturing

Patrick Hanley PhD

2:00 PM - 2:30 PM

CAR-T Therapies - A Manufacturing Blueprint

Emily Hopewell PhD

2:30pm - 2:45pm

Exhibitor and Coffee Break

2:45 PM - 3:15 PM

Development of Cell-Based Therapies to Achieve Tolerance Induction in Solid Organ Transplant

Joseph Leventhal MD

3:15 PM -3:45 PM

Immuno Correlative Assays in Cancer Cell Therapy

Tyce Kearl MD, PhD

3:45 PM - 4:15 PM

Interactive Panel Discussion

Jacques Galipeau, MD; Nadim Mahmud MD PhD; Emily Hopewell PhD; Patrick Hanley PhD and Mahzad Akbarpour PhD

4:15 PM - 4:30 PM

TBC Interactive Panel Discussion

Closing Remarks

Saturday, April 25th, 2026: Main Conference

7:00 AM - 8:00 AM
Non-CME Product Theater

SESSION I: LYMPHOMAS /LYMPHOID MALIGNANCIES
Chair: Mehdi Hamadani, MD

8:00am-8:10am

Welcome & Opening remarks

8:10am-8:30am

Harnessing Predictive Modeling for Individualized Therapy in Hodgkin Lymphoma

Andrew Evens, MD

8:30am-8:50am

How to select between CAR-T and targeted approaches and Relapsed/refractory mantle cell lymphoma

Brian Hill MD, PhD

8:50am-9:10am

Beyond CAR-T in R/R LBCLs

Farrukh Awan, MD

9:10am-9:30am

When to use allogeneic HCT in R/R T-cell NHL

Dipenkumar Modi, MD

9:30am-9:50am

Panel Discussion & Q & A

9:50am-10:10am

Exhibitor/Coffee Break

SESSION II: PLASMA CELL MALIGNANCIES/MYELOMA/AMYLOID
Chair: Patrick Hagen, MD

10:10am-10:30am

Immunotherapy in AL Amyloidosis: BiTEs, CARs and beyond

Taxiarchis Kourelis, MD

10:30am-10:50am

Role of up front ASCT-MRD Drive

Muhamed Baljevic MD, FACP

10:50am-11:10am

MM CAR-T Toxicities

Imran Puthawala, MD

11:10am-11:30am

Sequencing Immunotherapies in Multiple Myeloma

Binod Dhakal, MD

11:30am-11:50am

Plasma Cell Malignancy Panel Discussion

11:50am-12:50pm
Non-CME Product Theater

SESSION III: ACUTE LEUKEMIAS AND BMF
Chair: Celalettin Ustun, MD

12:50pm-1:10pm

CAR-T vs alloHCT in Acute Lymphoblastic Leukemia (ALL)

Wendy Stock, MD
1:10pm-1:30pm

Primary Myelofibrosis (PMF) Active problems and treatment

Jamille Shammo, MD

1:30pm-1:50pm

Acute Myeloid Leukemia (AML) current therapies

Geoffrey UY, MD

1:50pm-2:10pm

Recent Advances in Myelodysplastic Syndrome (MDS)

Olatoyosi Odenike, MD

2:10pm-2:30pm

Acute Leukemias and Bone Marrow Failure Panel

2:30pm-2:50pm

Coffee & Exhibitor Break

SESSION IV: MISCELLANEOUS
Chair: Sunita Nathan, MD

2:50pm-3:10pm

Frailty assessment and Pre Hab in HCT and Cell therapy patients

Magdelena Bednarczyk, MD

3:10pm-3:30pm

Alternative donor HCT -Access trial and impact of PTCY and Nuances

Antonio Jimenez, MD

3:30pm-3:50pm

CAR T Cell Therapy complication-focus on IEC HS

Sushma Bharadwaj, MD

3:50pm-4:10pm

Evolving Landscape of cellular therapy in solid tumors and focus on TiL therapy

John Hyngstrom, MD

4:10pm-4:30pm

Panel and Q & A

4:30pm

Adjourn